Common

Herbal medicinal product: Polypodii rhizomaArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of polypody rhizome.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing polypody rhizome.
  • Herbal medicines containing this polypody rhizome preparation are usually available as herbal tea to be drunk or in solid forms to be taken by mouth.
  • Polypody rhizome preparations may also be found in combination with other herbal substances in some herbal medicines.

Herbal medicinal product: Echinaceae purpureae herbaArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Herbal medicinal product: Echinaceae purpureae herbaArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Echinaceae purpureae herbaArray, C: ongoing call for scientific data

ELLKAY POWERS COMMONWELL TO ACHIEVE QHIN™

Retrieved on: 
Thursday, February 15, 2024

ELLKAY, a leader in interoperability for more than 20 years, is excited about its role as the technical service provider in helping CommonWell achieve this monumental milestone.

Key Points: 
  • ELLKAY, a leader in interoperability for more than 20 years, is excited about its role as the technical service provider in helping CommonWell achieve this monumental milestone.
  • ELLKAY is excited to play its role in enabling CommonWell and its members achieve this great milestone and is looking forward to providing a modern platform for data exchange," added Gurpreet 'GP' Singh, ELLKAY's Vice President of Interoperability Solutions.
  • Ajay Kapare, ELLKAY's President and Chief Strategy Officer, shared, "ELLKAY is excited about this next phase in our partnership with CommonWell.
  • To learn more about ELLKAY's partnership with CommonWell, stop by the ELLKAY at booths at ViVE #1336 or HIMSS #1547.

More Americans are Feeling Fatigued; MegaFood Launches 3-in-1 Iron Energy Gummies to Power Your Days

Retrieved on: 
Thursday, February 15, 2024

* While the Blood Builder iron supplements were developed for people with iron deficiency, MegaFood Iron Energy Gummies offers a lower potency formula with a moderate 4 mg of iron per serving to support the whole family's energy needs.

Key Points: 
  • * While the Blood Builder iron supplements were developed for people with iron deficiency, MegaFood Iron Energy Gummies offers a lower potency formula with a moderate 4 mg of iron per serving to support the whole family's energy needs.
  • *
    Since 60% of Americans report feeling fatigued,1 MegaFood is developing products to support healthy energy levels.
  • With over 40 years of experience expertly crafting iron supplements, MegaFood's Iron Energy Gummies are a solution for the whole family.
  • Iron Energy Gummies are non-GMO, vegan, gluten-free, and made with pectin and only 1 g of sugar per serving.

CARL PALMER'S 'FANFARE FOR THE COMMON MAN' DELUXE CAREER SPANNING 3 x CD & BLU-RAY BOX SET

Retrieved on: 
Thursday, February 15, 2024

LONDON, Feb. 15, 2024 /PRNewswire/ -- Carl Frederik Kendall Palmer was born on March 20th 1950 in Birmingham, England and his upbringing was far from smooth, his real father passed away when Carl was only 2. Raised by his step father in a very music minded family, Carl Palmer received his first drum on his 10th birthday and thus began a 60-year career that has seen Carl appear on a staggering 50million selling albums.

Key Points: 
  • Now BMG are proud to bring together Carl's impressive career across a 3 CD and 1 x Blu Ray Box Set featuring music and visuals from the Carl Palmer Band, Emerson, Lake & Palmer, Asia and various other Carl Palmer affiliated bands & artists among them The Craig, Chris Farlowe, Atomic Rooster and Mike Oldfield.
  • The Blu-Ray disc 'The Rhythm of Life' is an audio-visual documentary, narrated by Carl Palmer with live & exclusive behind-the-scenes footage featuring: ELP, ASIA, Crazy World Of Arthur Brown, Carl Palmer Band & ELP Legacy.
  • The documentary was created by long-time manager Bruce Pilato and Carl Palmer.
  • Tickets available at www.ELPTIckets.com
    As Carl Palmer approaches his 74th birthday he shows no sign of resting on his laurels.

Internist Shirin Peters, M.D. of Bethany Medical Clinic, Shares Top Tips for the Challenges of Winter Allergies

Retrieved on: 
Thursday, February 15, 2024

has identified at-home recommendations to combat winter allergy symptoms, helping allergy sufferers manage triggers, ease concerns, and avoid future flare-ups.

Key Points: 
  • has identified at-home recommendations to combat winter allergy symptoms, helping allergy sufferers manage triggers, ease concerns, and avoid future flare-ups.
  • “Many associate seasonal allergies just with spring but winter presents a different challenge to allergy sufferers.
  • Moreover, simple lifestyle changes and at-home tips can help manage symptoms and bring some relief during these cooler months,” says Dr. Peters, with Bethany Medical Clinic.
  • Dr. Peters shares preventative measures to decrease your chances of winter and indoor allergies and lower your risk of developing sinusitis and nasal polyps.

Magnolia Oil & Gas Corporation Announces 2023 Fourth Quarter and Year End Results

Retrieved on: 
Wednesday, February 14, 2024

Net cash provided by operating activities was $246.9 million during the fourth quarter of 2023 and $855.8 million during full year 2023.

Key Points: 
  • Net cash provided by operating activities was $246.9 million during the fourth quarter of 2023 and $855.8 million during full year 2023.
  • The Company generated free cash flow(1) of $131.3 million during the fourth quarter of 2023 and $412.9 million during full year 2023.
  • In the fourth quarter of 2023, production at Giddings and Other grew 46% compared to the prior year fourth quarter to 63.0 Mboe/d including oil production growth of 48%.
  • Magnolia repurchased 2.5 million Class A Common shares during the fourth quarter for $54.2 million.

Lancaster Colony Continues Higher Cash Dividend

Retrieved on: 
Wednesday, February 14, 2024

Lancaster Colony Corporation (Nasdaq: LANC) announced today that its Board of Directors has declared a quarterly cash dividend of 90 cents per common share, payable March 29, 2024 to shareholders of record on March 7, 2024.

Key Points: 
  • Lancaster Colony Corporation (Nasdaq: LANC) announced today that its Board of Directors has declared a quarterly cash dividend of 90 cents per common share, payable March 29, 2024 to shareholders of record on March 7, 2024.
  • The quarterly cash dividend amount of 90 cents per share maintains the higher level set three months ago, which marked the company’s 61st consecutive year of increased regular cash dividends.
  • Lancaster Colony is one of only 13 U.S. companies with 61 straight years of regular cash dividend increases.
  • CEO David A. Ciesinski said, “The dividend reflects the company’s continued strong financial position and will be the 243rd consecutive quarterly cash dividend paid by the company since September 1963.” He noted that the indicated annual payout for the current fiscal year ending June 30, 2024 is $3.55 per share, up from the $3.35 per share paid in fiscal 2023.

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Shineco Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Retrieved on: 
Wednesday, February 14, 2024

The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
  • The rights and privileges of the holders of shares of Common Stock will be substantially unaffected by the reverse stock split.
  • Transhare Corporation is acting as transfer and exchange agent for the reverse stock split.
  • Registered shareholders who hold shares of Common Stock are not required to take any action to receive post-reverse stock split shares.